期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

TA方案在局部晚期乳腺癌的治疗研究 被引量：1

The analysis of taxol and ADM in local advanced breast cancer
下载PDF
导出
摘要 目的探讨TA(泰素加阿霉素)化疗方案在局部晚期乳腺癌(T3N1M0除外)综合治疗中临床价值。方法用TA方案对28例局部晚期病人进行新辅助化疗2个疗程。结果28例中,完全缓解(CR)4例(14.3%),部分缓解(PR)22例(78.5%),无效(NC)1例(3.6%),进展(PD)1例(3.6%),总有效率92.8%。主要不良反应为消化道症状28例,脱发28例,心脏毒性2例,过敏反应11例,骨髓抑制4例,发热6例,头晕3例,肝功能异常1例。结论TA方案在局部晚期乳腺癌新辅助化疗中有较好疗效,临床应用毒性反应可耐受。 Objective To investigate the clinical value of TA (combined Taxol and ADM) chemotherapy in the associated treatment of local advanced breast cancer. Methods 28 patients with local advanced breast cancer were treated by two courses of Taxol and ADM as neoadjuvant chemotherapy. Results There were 22 cases of CR (14.3%),22 cases of PR(78.5%),one case of NC (3.6% and only one case of PD(3.6%), the total effective rate of 92.8%.Main side affects included digestive symptoms in 28 cases,hair loss in 28 cases,cardiotoxicity in 2 cases,hypersensitiviness in 11 cases,inhibition of bone marrow in 4 cases,fever in 6 cases,dizziness in 3 cases and liver function damage in 1 cases. Conclusion Taxol and ADM has a good effect in local advanced breast cancer as neoadjuvant chemotherapy.The clinical toxicity can be tolerated.
作者 方万强 吴瑞景 邓国敏 傅春利
机构地区 广东省开平市中心医院胸科
出处 《广州医药》 2005年第2期55-56,共2页 Guangzhou Medical Journal
关键词 局部晚期乳腺癌 TA方案 新辅助化疗 消化道症状 肝功能异常 临床价值 综合治疗 化疗方案 晚期病人 完全缓解 总有效率 不良反应 心脏毒性 过敏反应 骨髓抑制 毒性反应 临床应用 阿霉素 Local advanced breast cancer Neoadjuvant chemotherapy Taxol (Paclitaxel), Adriamycin
分类号 R737.9 [医药卫生—肿瘤] R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献5

二级参考文献38

  • 1徐建明,汤仲明,宋三泰,江泽飞,李家益,杨奕静.人乳腺癌原代培养体外药敏试验的评价[J].中华肿瘤杂志,1995,17(2):100-103. 被引量：22
  • 2[1]Inaji H, Komoike Y, Motomura K, et al. Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer[J]. Breast Cancer, 2002, 9(1):20～25
  • 3[2]Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer:predictors of breast-conservation therapy feasibility [J]. Ann Surg Oncol, 2002, 9(3):217～219
  • 4[3]Kuerer HM, Singletary SE, Brzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage Ⅱ and operable stage Ⅲ breast carcinoma[J]. Am J Surg, 2001,182(6):601～608
  • 5[4]Baslaim MM, A1 Malik OA, Al Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy[J]. Am J Surg, 2002, 184 (4): 299～301
  • 6[5]Gradishar WJ. Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer[J]. Clin Breast Cancer, 2001, 2(Suppl 1):S31～35
  • 7[6]Smith IC, Heys SD, Hutcheon AW, et al, Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[J]. J Clin Oncol 2002, 20 (6): 1456～1466
  • 8[7]De Matteis A, Nuzzo F, D'Aiuto G. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase Ⅱ study[J]. Cancer, 2002,94(4):895～901
  • 9[8]Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage Ⅲ primary breast cancer with primary chemotherapy,surgery, and radiation therapy[J]. Cancer, 1988, 62(12):2507～2516
  • 10[9]Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol, 1997, 15:2483～2495

共引文献69

同被引文献13

  • 1胡立平,苏健,刘智华,刘新.69例乳腺癌新辅助化疗临床报告[J].赣南医学院学报,2004,24(6):704-705. 被引量：1
  • 2刘贤铭.乳腺癌化疗药物的研究进展及临床应用评价[J].中国医院用药评价与分析,2005,5(4):214-216. 被引量：8
  • 3HENDERSON I C,BERRY D A,DEMETRI G D,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer[J].J Clin Oncol,2003,21 (6):976-983.
  • 4HEYS S D,SARKAR T,HUTCHEON A W.Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer[J].Expert Opin Pharmacother,2004,5 (10):2147-2157.
  • 5KUERER H M,NEWMAN L A,SMITH T L,et al.Clinical course of breast cancer patients with complete pathologic primary tumor and auxillarylymph node response to doxorubicin based neoadujvant chemotherapy[J].J Clin Oncol,1999,17(2):460-469.
  • 6DEO S V S,BHUTANI M,SHUKLA N,et al.Randomized trial comparing neo adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer(T4bN0-2M0)[J].Oncol Surg,2003,84(1):192-197.
  • 7INAJI H,KOMOIKE Y,MOTOMURA K,et al.Breast conserving treatment after neoadjuvant chemotherapy in large breast cancer[J].Breast Cancer,2002,9(1):20-25.
  • 8ALBA E,MARTIN M,RAMOS M,et al.Multicenter randomized trial comparing sequential with concomitan administration of doxorubicin and docetaxel as firstline treatment of metastatic breast cancer:a Spanish Breast Cancer Research Group (GEICAM29903) phse Ⅲ study[J].J Clin Oncol,2004,22(13):2587-2593.
  • 9BONNETERRE J,DIERAS V,TUBIANA H M,et al.Phase Ⅱ multicent rerandomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer[J].Br J Cancer,2004,91(8):1466-1471.
  • 10VENTURINI M,DURANDO A,GARRONE O,et al.Capecitahine in combination with docetaxet and epirubicin in patients with previously untreated,advanced breast carcinoma[J].Cancer,2003,97 (5):1174-1180.

引证文献1

二级引证文献2

广州医药
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部